D-W Kim

1.6k total citations · 1 hit paper
4 papers, 821 citations indexed

About

D-W Kim is a scholar working on Genetics, Rheumatology and Hematology. According to data from OpenAlex, D-W Kim has authored 4 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 4 papers in Rheumatology and 4 papers in Hematology. Recurrent topics in D-W Kim's work include Chronic Myeloid Leukemia Treatments (4 papers), Eosinophilic Disorders and Syndromes (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). D-W Kim is often cited by papers focused on Chronic Myeloid Leukemia Treatments (4 papers), Eosinophilic Disorders and Syndromes (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). D-W Kim collaborates with scholars based in Australia, United States and Germany. D-W Kim's co-authors include Timothy P. Hughes, Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson, Philipp D. le Coutre, Hagop M. Kantarjian, Ian W. Flinn, Gabriel Étienne, P.E. Dorlhiac‐Llacer and Hirohisa Nakamae and has published in prestigious journals such as Leukemia.

In The Last Decade

D-W Kim

4 papers receiving 806 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

2016 563 citations Andreas Hochhaus, Giuseppe Saglio et al. Leukemia profile →

Peers

Countries citing papers authored by D-W Kim

Since Specialization

Citations

This map shows the geographic impact of D-W Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D-W Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D-W Kim more than expected).

Fields of papers citing papers by D-W Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D-W Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D-W Kim. The network helps show where D-W Kim may publish in the future.

Co-authorship network of co-authors of D-W Kim

This figure shows the co-authorship network connecting the top 25 collaborators of D-W Kim. A scholar is included among the top collaborators of D-W Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D-W Kim. D-W Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

#	Work	Indexed citations
1	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial breakdown → 2016 ·Leukemia ·Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, D-W Kim, Surapol Issaragrisil, Philipp D. le Coutre, Gabriel Étienne, P.E. Dorlhiac‐Llacer, Richard E. Clark, Ian W. Flinn, Hirohisa Nakamae, (unknown), Weiping Deng, Darshan Dalal, Hans D. Menssen, Hagop M. Kantarjian	563
2	BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase 2015 ·Leukemia ·Timothy P. Hughes, Giuseppe Saglio, Alfonso Quintás‐Cardama, Michael J. Mauro, D-W Kim, Jeffrey H. Lipton, M. Brigid Bradley‐Garelik, Jon Ukropec, Andreas Hochhaus	52
3	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study 2012 ·Leukemia ·Francis J. Giles, Philipp D. le Coutre, Javier Pinilla‐Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, Jerald P. Radich, Giuseppe Saglio, Timothy P. Hughes, Giovanni Martinelli, D-W Kim, Steven Novick, Kris Gillis, Xingwen Fan, Jörge E. Cortes, Michele Baccarani, Hagop M. Kantarjian	177
4	Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value 2009 ·Leukemia ·Andreas Hochhaus, Martin C. Müller, Jerald P. Radich, Susan Branford, H. Kantarjian, Benjamin Hanfstein, Philippe Rousselot, D-W Kim, Jeffrey H. Lipton, Eric Bleickardt, Alexandre Lambert, Timothy P. Hughes	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact